A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/22/2001	US20010044419 Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells
11/22/2001	US20010044415 Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors
11/22/2001	US20010044411 Pain relieving and antiinflammatory drug, nutraceutical, and base, where one of drug or nutraceutical treats an ailment or symptom of an immune response, such as to a virus, microoganism, atmospheric pollutant or allergen
11/22/2001	US20010044410 Pain relieving and antiinflammatory drug, nutraceutical, and base, where one of drug or nutraceutical treats an ailment or symptom of an immune response, such as to a virus, microoganism, atmospheric pollutant or allergen
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010043959 Treating acid reflux disease or symptoms with a pharmaceutical such as cimetidine, famotidine, nizatidine, or ranitidine, and a nutraceutical such as ginger, licorice, or aloe vera extracts, and carrier
11/22/2001	US20010043957 For weight loss, a thermogenic/lipolytic composition such as ephedra, a neurotransmitter replacement composition such as huperazine-A, and antiinflammatory agent such as White Willow Bark
11/22/2001	US20010043956 Hangover cure
11/22/2001	US20010043955 Smilagenin and its use
11/22/2001	US20010043950 Core of fluvastatin, hydroxypropyl methyl cellulose and optionally other excipients, dosage form is color-stable during storage
11/22/2001	US20010043946 Tablet form with more than 76% by weight of gabapentin; made by spray coating with binder solution and compressing into non-friable tablets; improved compressibility, compactibility
11/22/2001	US20010043944 Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17- beta -estradiol to the human organism
11/22/2001	US20010043926 Pharmaceutical formulation
11/22/2001	US20010043908 Liquid oral compositions comprising a calcium compound and an acidulant
11/22/2001	US20010042936 Process for producing solid creatine dosage forms and dosage forms obtainable thereby
11/22/2001	DE10024989A1 DNA from the jellyfish Turritopsis nutricula useful as a rejuvenation agent for human beings
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	DE10018221A1 Treating disorders of the teeth, gums or jawbones using growth hormones, preferably human growth hormone or dehydroepiandrosterone, useful e.g. for treating paradontosis or healing jaw operation wounds
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2762960A1 Recrystallization processes for obtaining anhydrous optically active lansoprazole
11/22/2001	CA2410091A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	CA2410077A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001	CA2410067A1 Combination chemotherapy
11/22/2001	CA2410013A1 Pepsin inhibition by alginates
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409652A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409414A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	CA2409361A1 Humanised antibodies to the epidermal growth factor receptor
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409154A1 Compositions, kits, and methods for identification and modulation of t helper-1 and t helper-2 cells and diseases associated therewith
11/22/2001	CA2409116A1 Substituted thioacetamides
11/22/2001	CA2409063A1 7-substituted fused ring tetracycline compounds
11/22/2001	CA2409044A1 Improved recrystallization processes for obtaining anhydrous optically active lansoprazole
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2409005A1 Methods for decreasing cell proliferation based on (3r, 4r)-.delta.8-tetrahydrocannabinol-11-oic acids
11/22/2001	CA2408961A1 Use of ajulemic acid and related cannabinoids for the treatment of cancer
11/22/2001	CA2408913A1 Melanin-concentrating hormone antagonist
11/22/2001	CA2408849A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	CA2408842A1 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	CA2408837A1 New use of citreamicins
11/22/2001	CA2408830A1 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease
11/22/2001	CA2408719A1 Antiproliferative drug and delivery device
11/22/2001	CA2408689A1 Allantoin-containing skin cream
11/22/2001	CA2408667A1 Phosphate transport inhibitors
11/22/2001	CA2408608A1 Antiinflammatory drug and delivery device
11/22/2001	CA2408606A1 Drug combinations useful for prevention of restenosis
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2408383A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	CA2408373A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	CA2408246A1 Cell line for the expression of an .alpha.2.delta.2 calcium channel subunit
11/22/2001	CA2408163A1 Methods for treatment of inflammatory diseases
11/22/2001	CA2407540A1 Propofol for treatment of sepsis
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407259A1 Polyketide derivatives
11/22/2001	CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	CA2407254A1 Insulin formulation for inhalation
11/22/2001	CA2407222A1 New thiochromane derivatives and their use as thrombin inhibitors
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/22/2001	CA2407088A1 Beta-secretase inhibitors
11/22/2001	CA2406013A1 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	CA2405507A1 Use of pyrazole derivatives for treating infertility
11/22/2001	CA2404822A1 Fertilization of aged oocytes
11/22/2001	CA2404704A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/21/2001	EP1156118A1 Virus vector
11/21/2001	EP1156057A1 Malto-oligosaccharide derivatives and uses thereof
11/21/2001	EP1156050A2 Substituted tricyclics useful in sPLA2 induced diseases
11/21/2001	EP1156049A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
11/21/2001	EP1156047A1 6-substituted-7- heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both
11/21/2001	EP1156046A1 Benzo(5,6)cyclohepta(1,2-B)pyridine derivatives for the inhibition of farnesyl protein transferase
11/21/2001	EP1156044A1 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
11/21/2001	EP1156043A2 Drugs that enhance synaptic responses mediated by ampa receptors
11/21/2001	EP1156040A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
11/21/2001	EP1156039A1 Pyridazin-3-one derivatives and medicines containing the same
11/21/2001	EP1156037A1 Chondrongenesis promotors and indolin-2-one derivatives
11/21/2001	EP1156033A1 Process for producing acidic n-(long-chain acyl)amino acid
11/21/2001	EP1155702A1 Dds compounds and method for assaying the same
11/21/2001	EP1155701A1 Enteral sorbefacients
11/21/2001	EP1155699A1 Pharmaceutical and nutritional compositions comprising phytosterols, folic acid, cyanocobalamine, pyridoxine and alimentary fibers
11/21/2001	EP1155698A1 Organoboron compounds exhibiting anticoccidial activities
11/21/2001	EP1155697A1 Sustained release pharmaceutical composition containing glipizide and method for producing same
11/21/2001	EP1155696A2 Use of olanzapine for the manufacture of a medicament for neuroprotection
11/21/2001	EP1155695A1 1,3 oxathiolane nucleoside analogues
11/21/2001	EP1155694A1 Anti-hiv infection agents and method for treating hiv infection
11/21/2001	EP1155693A1 Intermittent claudication remedies
11/21/2001	EP1155692A1 Use of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
11/21/2001	EP1155691A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155690A2 Anti-angiogenic compositions and method of use
11/21/2001	EP1155689A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155677A2 Methods and compositions for inhibiting free radical polymerization in skin and hair
11/21/2001	EP1155361A2 Methods to reduce variance in treatment studies using genotyping
11/21/2001	EP1155304A2 A system for cell-based screening
11/21/2001	EP1155025A1 Platinum (ii) compounds
11/21/2001	EP1155021A1 Hesperitin pro-forms with enhanced bioavailability
11/21/2001	EP1155019A1 Substituted porphyrins
11/21/2001	EP1155018A1 Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo - 4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic

1 ... 5962 5963 5964 5965 5966 5967 5968 5969 5970 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 ... 7860